Meso Developing Active

Ipsen acquires Memo Therapeutics

Gaining traction — growing article coverage and momentum.

Score 0.5

Velocity ▲ 1.0

Articles 5

Sources 2

Top Movers

Ticker	Sector	Change
ABBV ⚡	Healthcare	-0.1%

Active Signals ABBV

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Sep 11, 2026 Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst … Bullish

Sep 06, 2026 Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats Neutral

Jul 30, 2026 Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could … Neutral

Jul 06, 2026 Besins Healthcare boosts drug delivery portfolio with UniD deal Neutral

Jul 01, 2026 Ipsen acquires Memo Therapeutics for up to $800 million Neutral

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? Yahoo Finance · Sep 11, 2026 Mixed

Top Movers

Ticker	Sector	Change
ABBV ⚡	Healthcare	-0.1%

Active Signals ABBV

🤖 AI Overview

PARAGRAPH 1
Ipsen, a French pharmaceutical company, has acquired Swiss biotech Memo Therapeutics for up to $800 million. The deal, announced on Wednesday, centers around potravitug, a Phase II monoclonal antibody for treating obesity. This acquisition follows Vertex's recent $10 billion takeover of Crinetics, suggesting increased M&A activity in the biotech sector, particularly in weight management pipelines.

PARAGRAPH 2
This acquisition impacts the biotech and pharmaceutical sectors, with companies like Viking Therapeutics potentially becoming the next takeover targets. The deal also signals a growing interest in obesity treatments, given potravitug's Phase II trial results. Ipsen's acquisition could drive further investment in obesity drug development, potentially boosting stocks in the sector.

PARAGRAPH 3
To watch next, investors should look out for:
1. Ipsen's Q3 earnings report, scheduled for October 28, which may provide more details on the Memo Therapeutics integration and the company's outlook on potravitug's development.
2. Regulatory decisions on potravitug, with a potential Phase III trial start in 2023, which could validate the drug's efficacy and safety.
3. Further M&A activity in the biotech sector, with Viking Therapeutics and other companies with promising obesity drug pipelines potentially becoming acquisition targets.

AI Overview as of Jul 30, 2026

Timeline

First SeenJul 30, 2026

Last UpdatedSep 12, 2026

Ipsen acquires Memo Therapeutics

Top Movers

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Related Articles